BIODESIX, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
BIODESIX, INC. (BDSX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$1.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-05
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $767.00K, a 67.18% decline year-over-year.
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$2.34M.
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $974.00K, a 42.50% decline year-over-year.
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $486.00K, a 21.86% decline year-over-year.
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $1.86M, a 13.56% increase from fiscal 2024.
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $1.64M, a 219.10% increase from fiscal 2023.
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $513.00K.
- BIODESIX, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$773.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $767.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.58M 10-Q · filed 2026-08-05 | -$603.00K derived: sum of 3 quarters · filed 2026-08-05 | -$117.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$2.34M 10-Q · filed 2026-05-04 | -$1.37M derived: sum of 2 quarters · filed 2026-05-04 | -$884.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $974.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.46M derived: sum of 2 quarters · filed 2026-02-26 | $3.80M derived: sum of 3 quarters · filed 2026-08-05 | $1.86M 10-K · filed 2026-02-26 |
| 2025-09-30 | $486.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $2.82M derived: sum of 2 quarters · filed 2026-08-05 | $885.00K 10-Q · filed 2025-11-03 | $2.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $399.00K 10-Q · filed 2026-08-05 | $2.09M derived: sum of 3 quarters · filed 2026-08-05 | $2.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.94M 10-Q · filed 2026-05-04 | -$244.00K derived: sum of 2 quarters · filed 2026-05-04 | $378.00K derived: sum of 3 quarters · filed 2026-05-04 | $933.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.32M derived: sum of 2 quarters · filed 2026-02-26 | $2.87M derived: sum of 3 quarters · filed 2026-02-26 | $1.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | $622.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $1.18M derived: sum of 2 quarters · filed 2025-11-03 | -$57.00K 10-Q · filed 2025-11-03 | $703.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $555.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$679.00K 10-Q · filed 2025-08-07 | $81.00K derived: sum of 3 quarters · filed 2025-08-07 | -$1.40M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.23M 10-Q · filed 2025-05-13 | -$474.00K derived: sum of 2 quarters · filed 2025-05-13 | -$1.96M derived: sum of 3 quarters · filed 2025-05-13 | $1.31M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$723.00K derived: sum of 2 quarters · filed 2025-03-03 | $2.54M derived: sum of 3 quarters · filed 2025-03-03 | $513.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $1.78M derived: sum of 2 quarters · filed 2024-11-01 | -$247.00K 10-Q · filed 2024-11-01 | -$374.00K derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.24M 10-Q · filed 2024-08-07 | $1.11M derived: sum of 3 quarters · filed 2024-08-07 | $1.66M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$2.03M 10-Q · filed 2024-05-08 | -$2.16M derived: sum of 2 quarters · filed 2024-05-08 | -$1.61M derived: sum of 3 quarters · filed 2024-05-08 | -$1.50M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $422.00K derived: sum of 2 quarters · filed 2024-03-01 | $531.00K derived: sum of 3 quarters · filed 2024-03-01 | -$773.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | $549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $658.00K derived: sum of 2 quarters · filed 2023-11-07 | -$646.00K 10-Q · filed 2023-11-07 | $1.19M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$1.20M 10-Q · filed 2023-08-07 | $642.00K derived: sum of 3 quarters · filed 2023-08-07 | $833.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$1.30M 10-Q · filed 2023-05-11 | $533.00K derived: sum of 2 quarters · filed 2023-05-11 | $724.00K derived: sum of 3 quarters · filed 2023-05-11 | -$2.98M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.03M derived: sum of 2 quarters · filed 2023-03-06 | -$1.68M derived: sum of 3 quarters · filed 2023-03-06 | -$7.42M 10-K · filed 2023-03-06 |
| 2021-09-30 | $191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.52M derived: sum of 2 quarters · filed 2022-11-03 | -$9.26M 10-Q · filed 2022-11-03 | -$2.98M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$3.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$9.45M 10-Q · filed 2022-08-04 | -$3.17M derived: sum of 3 quarters · filed 2022-08-04 | $2.41M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$5.74M 10-Q · filed 2022-05-11 | $541.00K derived: sum of 2 quarters · filed 2022-05-11 | $6.12M derived: sum of 3 quarters · filed 2022-05-11 | $5.05M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $11.86M derived: sum of 2 quarters · filed 2022-03-14 | $10.80M derived: sum of 3 quarters · filed 2022-03-14 | $11.65M 10-K · filed 2022-03-14 |
| 2020-09-30 | $5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $4.51M derived: sum of 2 quarters · filed 2021-11-15 | $5.37M 10-Q · filed 2021-11-15 | $4.84M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$210.00K 10-Q · filed 2021-08-10 | -$739.00K derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | $857.00K 10-Q · filed 2021-05-11 | $328.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$529.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $1.19M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $1.72M 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |